Bulletin
Investor Alert
×

May 7, 2019, 9:01 a.m. EDT

CareDx's AlloSeq cfDNA and QTYPE Solutions Featured at EFI 2019

CareDx leadership in transplant innovation highlighted through multiple podium and poster presentations

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    CareDx Inc. (CDNA)

or Cancel Already have a watchlist? Log In

BRISBANE, May 07, 2019 (GLOBE NEWSWIRE via COMTEX) -- CareDx, Inc. /zigman2/quotes/200138382/composite CDNA -4.94% , a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that new data from studies on AlloSeq cfDNA and QTYPE will be featured in multiple podium and poster presentations at the annual European Immunogenetics and Histocompatibility Conference (EFI) in Lisbon, Portugal on May 8-11, 2019.

CareDx continues its dedication to innovation in transplantation with two oral presentations and three posters at EFI, and highlights its leadership with the only presentations on cfDNA in transplantation.

Additionally, CareDx will host a lunch symposium titled "Innovation in Transplant Diagnostics: Pushing the Boundaries of Transplant Solutions" on Thursday, May 9, 2019, 12:15 p.m. - 1:00 p.m. at the Centro Cultural de Belem. The symposium features two leaders in the transplant field:

-- Gottfried Fischer, MD, Medical University of Vienna, presenting data on AlloSeq cfDNA

-- Milena Vrana, Head of HLA department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic presenting data on QTYPE

Oral Presentations

Donor-Derived Cell-Free DNA Correlates With Rejection in Kidney Allografts

TARGETED Gene Sequencing Following Enrichment using Capture Probes: The Next Generation of Genetic Matching in Transplantation

Poster Presentation

Donor-Derived Cell-Free DNA Levels Are Independent Of Degree Of Mismatch and Donor Type

AlloSeq CfDNA, A Donor-Derived Cell-Free DNA Measurement Solution For On-Site Monitoring of Solid Organ Transplants

QTYPE, the Fastest Method for HLA Genotyping by Real-Time PCR

"Transplant is global and CareDx is committed to providing best in class solutions for transplant patients around the world," said Peter Maag, Chief Executive Officer at CareDx. "These abstracts and presentations highlight CareDx's position as a leading provider of genomics-based information in transplantation, with the goal to improve long-term patient outcomes. We collaborate with the many distinguished clinicians in transplantation, and look forward to having them share their latest insights with the broader community at EFI."

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: www.CareDx.com .

Forward Looking Statements

/zigman2/quotes/200138382/composite
US : U.S.: Nasdaq
$ 30.96
-1.61 -4.94%
Volume: 1.79M
July 17, 2019 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.37 billion
Rev. per Employee
$331,468
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.